Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1954 1
1963 2
1965 2
1966 2
1967 1
1968 3
1969 1
1970 3
1971 6
1972 6
1973 4
1974 9
1975 6
1976 5
1977 10
1978 11
1979 6
1980 11
1981 18
1982 10
1983 25
1984 21
1985 16
1986 19
1987 23
1988 16
1989 22
1990 20
1991 24
1992 26
1993 19
1994 20
1995 21
1996 21
1997 19
1998 29
1999 30
2000 35
2001 49
2002 34
2003 45
2004 58
2005 69
2006 36
2007 53
2008 66
2009 70
2010 86
2011 90
2012 93
2013 93
2014 94
2015 120
2016 126
2017 145
2018 92
2019 135
2020 143
2021 160
2022 151
2023 16
Text availability
Article attribute
Article type
Publication date

Search Results

2,313 results
Results by year
Filters applied: . Clear all
Page 1
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.
Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, Kudo M, Breder V, Merle P, Kaseb AO, Li D, Verret W, Xu DZ, Hernandez S, Liu J, Huang C, Mulla S, Wang Y, Lim HY, Zhu AX, Cheng AL; IMbrave150 Investigators. Finn RS, et al. Among authors: kudo m. N Engl J Med. 2020 May 14;382(20):1894-1905. doi: 10.1056/NEJMoa1915745. N Engl J Med. 2020. PMID: 32402160 Clinical Trial.
NASH limits anti-tumour surveillance in immunotherapy-treated HCC.
Pfister D, Núñez NG, Pinyol R, Govaere O, Pinter M, Szydlowska M, Gupta R, Qiu M, Deczkowska A, Weiner A, Müller F, Sinha A, Friebel E, Engleitner T, Lenggenhager D, Moncsek A, Heide D, Stirm K, Kosla J, Kotsiliti E, Leone V, Dudek M, Yousuf S, Inverso D, Singh I, Teijeiro A, Castet F, Montironi C, Haber PK, Tiniakos D, Bedossa P, Cockell S, Younes R, Vacca M, Marra F, Schattenberg JM, Allison M, Bugianesi E, Ratziu V, Pressiani T, D'Alessio A, Personeni N, Rimassa L, Daly AK, Scheiner B, Pomej K, Kirstein MM, Vogel A, Peck-Radosavljevic M, Hucke F, Finkelmeier F, Waidmann O, Trojan J, Schulze K, Wege H, Koch S, Weinmann A, Bueter M, Rössler F, Siebenhüner A, De Dosso S, Mallm JP, Umansky V, Jugold M, Luedde T, Schietinger A, Schirmacher P, Emu B, Augustin HG, Billeter A, Müller-Stich B, Kikuchi H, Duda DG, Kütting F, Waldschmidt DT, Ebert MP, Rahbari N, Mei HE, Schulz AR, Ringelhan M, Malek N, Spahn S, Bitzer M, Ruiz de Galarreta M, Lujambio A, Dufour JF, Marron TU, Kaseb A, Kudo M, Huang YH, Djouder N, Wolter K, Zender L, Marche PN, Decaens T, Pinato DJ, Rad R, Mertens JC, Weber A, Unger K, Meissner F, Roth S, Jilkova ZM, Claassen M, Anstee QM, Amit I, Knolle P, Becher B, Llovet JM, Heikenwalder M. Pfister D, et al. Among authors: kudo m. Nature. 2021 Apr;592(7854):450-456. doi: 10.1038/s41586-021-03362-0. Epub 2021 Mar 24. Nature. 2021. PMID: 33762733 Free PMC article.
Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma.
Cheng AL, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, Lim HY, Kudo M, Breder V, Merle P, Kaseb AO, Li D, Verret W, Ma N, Nicholas A, Wang Y, Li L, Zhu AX, Finn RS. Cheng AL, et al. Among authors: kudo m. J Hepatol. 2022 Apr;76(4):862-873. doi: 10.1016/j.jhep.2021.11.030. Epub 2021 Dec 11. J Hepatol. 2022. PMID: 34902530 Free article. Clinical Trial.
Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial.
Yau T, Park JW, Finn RS, Cheng AL, Mathurin P, Edeline J, Kudo M, Harding JJ, Merle P, Rosmorduc O, Wyrwicz L, Schott E, Choo SP, Kelley RK, Sieghart W, Assenat E, Zaucha R, Furuse J, Abou-Alfa GK, El-Khoueiry AB, Melero I, Begic D, Chen G, Neely J, Wisniewski T, Tschaika M, Sangro B. Yau T, et al. Among authors: kudo m. Lancet Oncol. 2022 Jan;23(1):77-90. doi: 10.1016/S1470-2045(21)00604-5. Epub 2021 Dec 13. Lancet Oncol. 2022. PMID: 34914889 Clinical Trial.
Autoimmune hepatitis and IgG4-related disease.
Minaga K, Watanabe T, Chung H, Kudo M. Minaga K, et al. Among authors: kudo m. World J Gastroenterol. 2019 May 21;25(19):2308-2314. doi: 10.3748/wjg.v25.i19.2308. World J Gastroenterol. 2019. PMID: 31148902 Free PMC article. Review.
Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma.
Finn RS, Ikeda M, Zhu AX, Sung MW, Baron AD, Kudo M, Okusaka T, Kobayashi M, Kumada H, Kaneko S, Pracht M, Mamontov K, Meyer T, Kubota T, Dutcus CE, Saito K, Siegel AB, Dubrovsky L, Mody K, Llovet JM. Finn RS, et al. Among authors: kudo m. J Clin Oncol. 2020 Sep 10;38(26):2960-2970. doi: 10.1200/JCO.20.00808. Epub 2020 Jul 27. J Clin Oncol. 2020. PMID: 32716739 Free PMC article. Clinical Trial.
Therapeutic Potential of Centella asiatica and Its Triterpenes: A Review.
Sun B, Wu L, Wu Y, Zhang C, Qin L, Hayashi M, Kudo M, Gao M, Liu T. Sun B, et al. Among authors: kudo m. Front Pharmacol. 2020 Sep 4;11:568032. doi: 10.3389/fphar.2020.568032. eCollection 2020. Front Pharmacol. 2020. PMID: 33013406 Free PMC article. Review.
Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial.
Yau T, Kang YK, Kim TY, El-Khoueiry AB, Santoro A, Sangro B, Melero I, Kudo M, Hou MM, Matilla A, Tovoli F, Knox JJ, Ruth He A, El-Rayes BF, Acosta-Rivera M, Lim HY, Neely J, Shen Y, Wisniewski T, Anderson J, Hsu C. Yau T, et al. Among authors: kudo m. JAMA Oncol. 2020 Nov 1;6(11):e204564. doi: 10.1001/jamaoncol.2020.4564. Epub 2020 Nov 12. JAMA Oncol. 2020. PMID: 33001135 Free PMC article. Clinical Trial.
Biology and significance of alpha-fetoprotein in hepatocellular carcinoma.
Galle PR, Foerster F, Kudo M, Chan SL, Llovet JM, Qin S, Schelman WR, Chintharlapalli S, Abada PB, Sherman M, Zhu AX. Galle PR, et al. Among authors: kudo m. Liver Int. 2019 Dec;39(12):2214-2229. doi: 10.1111/liv.14223. Epub 2019 Sep 11. Liver Int. 2019. PMID: 31436873 Review.
2,313 results